9.890USD-0.40%Mkt Cap: 343.55M USDP/E: —Last update: 2026-05-26
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cispl…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap343.55M USD
Enterprise Value306.15M USD
Revenue (TTM)51.00M USD
Gross Profit40.88M USD
Net Income (TTM)-9.74M USD
Revenue/Share1.685 USD
Last Price9.890 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINCA31447P1009
Valuation
P/E (Trailing)—
P/E (Forward)9.60
PEG1.47
EV/EBITDA-55.76
EV/Revenue6.00
P/S6.79
P/B9.14
EPS (TTM)-0.29
EPS (Forward)1.04
52W Range
5.65088% of range10.45
52W High10.45 USD
52W Low5.650 USD
Profitability
Gross Margin91.57%
Oper. Margin-0.79%
EBITDA Margin-10.77%
Profit Margin-21.82%
ROE-27.46%
ROA-13.81%
Growth
Revenue Growth72.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.47M USD
CapEx (TTM)—
FCF Margin-4.65%
FCF Yield-0.69%
Net Debt-40.18M USD
Net Debt/EBITDA7.32
Balance Sheet
Debt/Equity0.00
Current Ratio6.98
Quick Ratio6.15
Book Value/Sh1.091 USD
Cash/Share1.157 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)15.17 USD
Target Range13.00 USD – 18.00 USD
# Analysts6
Ownership
Shares Out.34.74M
Float16.88M
Insiders14.39%
Institutions54.30%
Short Interest
Short Ratio7.1d
Short % Float3.54%
Short % Out.3.05%
Shares Short1.06M
Short (prev mo.)913.27K
Technical
SMA 507.056 (+40.2%)
SMA 2007.959 (+24.3%)
Beta0.91
S&P 52W Chg28.31%
Avg Vol (30d)248.12K
Avg Vol (10d)468.62K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—